Hodgkin’s Lymphoma after Autologous Stem-Cell Transplantation: Effective Consolidation with Brentuximab Vedotin
Patients with recurrent or refractory Hodgkin’s lymphoma who are at increased risk of progression after high-dose chemotherapy and autologous stem-cell transplantation may benefit from consolidation therapy with brentuximab vedotin, according to the results of the AETHERA study.^1,2^ Based on clinic...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2020-11-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2020.06.025 |
| Summary: | Patients with recurrent or refractory Hodgkin’s lymphoma who are at increased risk of progression after high-dose chemotherapy and autologous stem-cell transplantation may benefit from consolidation therapy with brentuximab vedotin, according to the results of the AETHERA study.^1,2^ Based on clinical trial data, brentuximab vedotin in combination with adriblastina, vinblastine and dacarbazine (AVD) represents a good treatment option as the frontline therapy for Hodgkin’s lymphoma^3^ as well as in the sequential treatment of older patients.^4^ This report presents the case of a patient with relapsed/refractory cHL who received brentuximab vedotin maintenance after an inadequate response to first-line adriblastina, bleomycin, vinblastine and dacarbazine (ABVD) and reinduction chemotherapy with dexamethasone, high-dose cytarabine, platinum (cisplatin) (DHAP). Despite the high-risk features and multiple complications that occurred during the disease course, the patient is still in remission 3 years after the end of maintenance therapy. |
|---|---|
| ISSN: | 2673-2092 2673-2106 |